Tetratherix Limited (ASX:TTX) CEO Will Knox has delivered remarks at the company's 2026 Annual General Meeting on 12 November 2026, disclosing that the company closed FY26 with $34.4 million in cash, having secured more than $20 million beyond its prospectus assumptions, and confirmed the completion of its first full FDA submissions in its bone regeneration franchise.

Key Points

  • Tetratherix closed FY26 with $34.4 million in cash, securing more than $20 million beyond prospectus assumptions
  • The company completed its first full FDA submissions in its bone regeneration franchise, supported by twenty-seven technical reports, the complete ISO 10993 safety package, and two FDA performance studies
  • The FDA assigned the Tetramatrix polymer its own federal identifier as an approved excipient
  • More than 75 patients have now been treated with Tetramatrix, a 58 per cent increase on the year before
  • An exclusive global supply agreement was signed with Henry Schein, and ophthalmic technology was licensed to BioOptix, which has partnered with Alcon

FDA Submissions and Regulatory Progress in Bone Regeneration

According to the filing, Tetratherix completed its first full FDA submissions in its bone regeneration franchise during FY26. The submissions were supported by twenty-seven technical reports, the complete ISO 10993 safety package, and two FDA performance studies. In the company's precision medicine program, the FDA assigned the Tetramatrix polymer its own federal identifier as an approved excipient. The company said it is working toward FDA clearance for its bone regeneration products, to be followed by a seeding program across dental, orthopaedics, and its first regenerative product sales.

Commercial Partnerships and Revenue Generation

The filing states that Tetratherix became a revenue-generating company in FY26. The company signed an exclusive global supply agreement with Henry Schein, described in the filing as one of the largest medical and dental companies in the world. Tetratherix also licensed its ophthalmic technology to BioOptix, which has partnered with Alcon, identified in the filing as the leading player in the ophthalmic space globally, through which the Optimatrix program is being executed. The company disclosed that its six first-generation products come from three polymer configurations sharing around 95 per cent of their chemistry.

Clinical Evidence and Program Updates

The filing disclosed that Tutelix completed its first-in-human pilot study with no product-related adverse events and proven efficacy aligned with design and development objectives, and holds ethics approval for its pivotal trial getting underway in 2026. TetraDerm completed full enrolment and moved into the largest wounds in surgery, with blinded results expected in 2027. More than 75 patients have now been treated with Tetramatrix, representing a 58 per cent increase on the year before. The filing also noted that five years of work in nasal drug delivery became a new franchise, Precision Medicine, with STEPP at its centre.